Dasatinib Monohydrate

• CAT Number: A000113
• CAS Number: 863127-77-9
• Molecular Formula: C22H28ClN7O3S
• Molecular Weight: 506.02
• Purity: ≥95%
• Synonyms: BMS-354825 Monohydrate
• Storage: Store at -20°C
• IUPAC Name: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide;hydrate
• InChI: InChI=1S/C22H26ClN7O2S.H2O/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31;/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27);1H2
• InChIKey: XHXFZZNHDVTMLI-UHFFFAOYSA-N
• SMILES: CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO.O

Dasatinib Monohydrate（Cat No.:A000113）is a potent tyrosine kinase inhibitor that targets BCR-ABL, Src family kinases, and several other kinases involved in cancer cell proliferation. It is primarily used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). By inhibiting the BCR-ABL fusion protein, dasatinib halts abnormal cell signaling that drives cancer growth. Its broad activity across multiple kinases also helps address resistance to previous treatments. Dasatinib Monohydrate is widely regarded for its effectiveness in managing hematologic malignancies and improving patient outcomes.